Literature DB >> 16554104

The paradox of Epstein-Barr virus-associated hepatitis.

Francesco Negro.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16554104     DOI： 10.1016/j.jhep.2006.03.002

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  7 in total

1.  Acute hepatitis due to epstein-barr virus in an immunocompetent patient.

Authors:  Neha Pagidipati; Keith L Obstein; Rachel Rucker-Schmidt; Robert D Odze; Christopher C Thompson
Journal:  Dig Dis Sci       Date:  2009-05-21       Impact factor: 3.199

2.  Severe EBV hepatitis treated with valganciclovir.

Authors:  R Pisapia; A Mariano; A Rianda; A Testa; A Oliva; L Vincenzi
Journal:  Infection       Date:  2012-07-27       Impact factor: 3.553

3.  Virological and immunological characteristics of fatal Epstein-Barr virus mononucleosis in a 17-year-old Caucasian male presenting with meningoencephalitis and hemophagocytic syndrome.

Authors:  Adriana Vince; Snjezana Zidovec Lepej; Ivan Kurelac; Bruno Barsic; Sanja Kozic; Igor Klinar; Kamelia Zarkovic
Journal:  J Neurovirol       Date:  2007-08       Impact factor: 2.643

4.  EBV Chronic Infections.

Authors:  Pizzigallo Eligio; Racciatti Delia; Gorgoretti Valeria
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-10       Impact factor: 2.576

5.  Jaundice as a Rare Manifestation of Epstein-Barr Virus Primary Infection.

Authors:  Lígia Rodrigues Santos; Margarida Silva Cruz; Rita Veiga Ferraz; Vera Ferraz Moreira; Alice Castro
Journal:  Cureus       Date:  2021-06-12

6.  Antiviral Drugs for EBV.

Authors:  Joseph S Pagano; Christopher B Whitehurst; Graciela Andrei
Journal:  Cancers (Basel)       Date:  2018-06-13       Impact factor: 6.639

7.  Syphilis Reactivates Latent Epstein-Barr Virus Reservoir via Toll-Like Receptor 2 and B-Cell Receptor Activation.

Authors:  Julia R Hirsiger; Philipp S Fuchs; Peter Häusermann; Bojana Müller-Durovic; Thomas Daikeler; Mike Recher; Hans H Hirsch; Luigi Terracciano; Christoph T Berger
Journal:  Open Forum Infect Dis       Date:  2019-07-03       Impact factor: 3.835
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.